Aptar Digital Health Partners with Enable Injections for enFuse Companion Digital Solution

Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (Enable), a healthcare innovation company developing and manufacturing the enFuse On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable’s preferred digital health partner for the enFuse system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help strengthen engagement support before, during and after administration. 

Through this partnership, Aptar Digital Health will deliver a companion digital solution for Enable Injections’ enFuse system, designed to enhance the patient experience and support adherence. Key features of the solution will include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes and symptom tracking - helping to empower patients and caregivers with greater confidence and control over the treatment process. 

Built on a flexible and scalable architecture, the companion solution will be deployed alongside the enFuse system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. Designed to evolve across the drug development lifecycle, the solution will support use cases from clinical trials through commercialisation, aligned with development and launch strategies.

Adherence data and patient-reported outcomes will be captured remotely, securely stored and made available through analytics dashboards that generate actionable insights to support clinical development, launch readiness and real-world use. The modular, program-specific design will allow pharmaceutical partners to integrate digital components into their clinical or commercial programs based on their needs. By combining device-generated data with patient-reported insights, the solution will help drive more informed decisions grounded in real-world usage. 

“The enFuse companion solution reflects our vision of a more connected treatment experience that supports patients beyond the moment of injection,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “Together with Aptar Digital Health, we aim to combine innovative drug delivery with digital support tools that can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient’s journey.” 

“We are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,” said Damien McKeon, SVP Strategic Partnerships, Aptar Digital Health. “Large-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.”